BACKGROUND AND STUDY AIMS: Five- @entity8454 ( @entity2518 ) is being increasingly used for photodynamic diagnosis and therapy of various types of @entity5 including brain, urologic, and other @entity5 . The use of @entity2518 to treat @entity189 has been documented, but its clinical effectiveness for diagnosis of @entity1820 , particularly early @entity5 , remains unknown. @entity1 AND METHODS: The aim of our feasibility study was to evaluate the visibility of @entity14 using endoscopic fluorescence imaging (EFI) after oral administration of @entity2518 . The lesions identified by direct visualization and by the spectrums produced using EFI modality with @entity2518 were compared to the clinicopathologic features of resected specimens. RESULTS: Twenty-three @entity1 with a total of 27 known @entity14 were enrolled in the study. The median @entity5 size was 30mm (range 10-75). Eleven of the lesions were flat or @entity308 and 16 were sessile. Red fluorescence was observed in 22 out of 27 lesions. Red fluorescence was negative in 4 out of 11 flat or @entity308 . In comparison with histopathologic findings, the rates of red fluorescence visibility were 62.5% in low-grade intraepithelial @entity5 , 77.8% in high-grade @entity5 , and 100% in @entity189 . Red fluorescence visibility increased with the degree of @entity1141 . There were no significant adverse events identified in this study. CONCLUSIONS: This feasibility study using EFI with @entity2518 demonstrated high visibility of superficial @entity14 . EFI with @entity2518 appears to be a novel, safe technique for improving real-time @entity14 imaging.

Evaluating the efficacy and safety of a novel endoscopic fluorescence imaging modality using oral @entity2518 for XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity308 :: ('MESH:D003866', 'Disease') :: ['depressed lesions'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplasias', 'cancers', 'neoplasia', 'tumors'] @entity189 :: ('MESH:D002277', 'Disease') :: ["Barrett's carcinomas", 'submucosal carcinoma'] @entity2518 :: ('CHEBI:17549', 'Chemical') :: ['5-ALA'] @entity1820 :: ('MESH:D005770', 'Disease') :: ['gastrointestinal tumors'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal lesions', 'colorectal neoplasia', 'colorectal tumor', 'colorectal tumors'] @entity8454 :: ('MESH:D000622', 'Chemical') :: ['aminolevulinic acid'] @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal tumors']
